MedTrace Logo

Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation

NCT00513019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-02-23

Study results available
· View outcomes & findings →

Summary

The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Conditions

  • Neurotic Excoriation
  • Pathologic Skin Picking
  • Psychogenic Excoriation
  • Dermatillomania

Interventions

DRUG

Lamictal (lamotrigine)

once daily from beginning to end of study. Dosage varies.

DRUG

Placebo

daily

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon E Grant, M.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513019 on ClinicalTrials.gov